Table 1. Cytogenetic and molecular response rates of large clinical trials testing first-line high-dose imatinib in chronic-phase chronic myeloid leukemia. Study (year) Trial Response (%) Ref.

ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to ...

ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for which patients chronic drug treatment could potentially be ...

Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine ...

a phase II clinical study was undertaken to evaluate the activity of nilotinib as first-line treatment for patients with previously untreated, early-stage chronic-phase Ph+ CML. In total ...

“Therefore, we believe that olverembatinib, with its real-world patient data in China, where it is approved, has the potential to be a global therapy for CML.” An ongoing Phase 3 clinical ...

For instance, in one of the first clinical studies described in medical ... responses were observed in 53 of 54 patients with CML treated with daily dosage of 300 mg or more and typically occurred ...

Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and ...

Revenue in 2024 increased 342%year-over-year to US$134.3 million (RMB980.7 million), attributable in part to Takeda’s option payment and strong ...